At AAIC 2026, data show LEQEMBI subcutaneous autoinjector (SC-AI) delivers efficacy and safety comparable to IV initiation for early Alzheimer’s disease, suggesting a convenient at-home initiation and maintenance pathway if approved by the FDA.

The presentation indicates SC-AI may offer similar efficacy and safety to IV lecanemab initiation, with potential for at-home treatment once regulatory approval is granted.

LEQEMBI, from Eisai and Biogen, now has AAIC 2026 data indicating the SC-AI formulation matches IV initiation in efficacy and safety for early Alzheimer’s disease.

The release includes standard biopharma context such as notes on protofibrils, collaboration history, and forward-looking statements.

Early and ongoing SC initiation and maintenance could improve long-term disease management, flexibility, and accessibility for patients and caregivers.

Real-world data from two U.S. centers show SC administration associated with slower cognitive decline (CDR-SB) over 36 months in one cohort and MMSE stability/improvement in another, with high satisfaction and willingness to recommend.

Clinically, SC use demonstrated slower decline versus natural history and strong patient/caregiver satisfaction, with convenience and willingness to recommend consistently high.

Treatment pathways emphasize flexibility, including switching between IV and SC and dosing adjustments if a dose is missed (next day to day six).

A 500 mg weekly SC-AI dose achieved bioequivalence to the IV initiation regimen, with stable exposure across body weight groups supporting a fixed-dose approach.

SC-AI initiation showed consistent pharmacokinetics, amyloid clearance, and clinical outcomes across weight quartiles, reinforcing a fixed-dose strategy.

Eisai leads lecanemab development with Biogen, and SC maintenance (IQLIK) regulatory work ongoing in the U.S. and other regions as part of a broader development program.

The data point to feasible at-home initiation and maintenance if the FDA approves SC initiation, potentially expanding access across care settings.